ZyVersa Therapeutics, Inc. (ZVSA) - Cekelan dhuwit saben saham

Lambang korporat lan logo ZyVersa (ZVSA)

ZyVersa Therapeutics positions itself as a leader in the therapy of renal pathologies through the suppression of inflammation, and analyzing the cash per share metric on GURU.Markets, we note that the current figure is 0.00. Optimizing biochemistry supplies across various laboratories protects future profits. However, a liquidity deficit and early-stage testing force the company to regularly raise capital through share issuances.

ZyVersa Therapeutics, Inc. (ZVSA) - Dana dhuwit saben saham saka 28.04.2023 nganti 02.08.2025

Rincian analitis perusahaan zyversa.com (ZVSA)

- indikator kapitalisasi pasar:
- rincian posisi dhuwit lan arus kas:
Analisis umum perusahaan:ZyVersa Therapeutics, Inc., ZVSA
Barang utama ZyVersa Therapeutics

This metric reflects the amount of cash per common share, determining the issuer's internal liquidity reserve. By analyzing the level of liquid assets per share, an investor assesses the ability of ZyVersa Therapeutics (ZVSA) to fund costly FDA trials. This resource is critical for protecting margins amidst the patent wars of the biopharmaceutical sector. The stability of this metric confirms the business's financial resilience, whereas excess cash may conversely signal inefficient capital management.